ISIziah Edwin Sama

Iziah Edwin Sama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Iziah Edwin Sama has a total of 174 co-authors. Here are the top co-authors by number of shared publications:

  • Kenneth Dickstein

    University of Bergen, Stavanger University Hospital Stavanger Norway

    9 shared publications
  • Adriaan Alexander Voors

    University of Groningen, the Netherlands (A.A.V.).

    8 shared publications
  • Marco Metra

    Institute of Cardiology, ASST Spedali Civili di Brescia, and Department of Medical and Surgical Specialties Radiological Sciences and Public Health, University of Brescia Brescia Italy

    8 shared publications
  • Leong Loke Ng

    Department of Cardiovascular Sciences, College of Life Sciences (T.H.C., P.A.Q., L.L.N., A.A.B.-C., T.W., D.A.), University of Leicester, United Kingdom

    6 shared publications
  • Adriaan A. Voors

    University of Groningen, University Medical Center Groningen Groningen The Netherlands

    5 shared publications
  • Gerasimos Filippatos

    National and Kapodistrian University of Athens Athens University Hospital Attikon Athens Greece

    5 shared publications

Latest Publications

  • Open Access

    Distinct pathophysiological pathways in women and men with heart failure

    by Alice Ravera, Bernadet T. Santema, Rudolf A. de Boer, Stefan D. Anker, Nilesh J. Samani, Chim C. Lang, Leong Ng, John G.F. Cleland, Kenneth Dickstein, Carolyn S.P. Lam, et al.

    Aims: Clinical differences between women and men have been described in heart failure (HF). However, less is known about the underlying pathophysiological mechanisms. In this study, we compared multiple circulating biomarkers to gain better insights into differential HF pathophysiology between women and men. Methods and results: In 537 women and 1485 men with HF, we compared differential expression of a panel of 363 biomarkers. Then, we performed a pathway over‐representation analysis to identify differential biological pathways in women and men. Findings were validated in an independent HF cohort (575 women, 1123 men). In both cohorts, women were older and had higher left ventricular ejection fraction (LVEF). In the index and validation cohorts respectively, we found 14/363 and 12/363 biomarkers that were relatively up‐regulated in women, while 21/363 and 14/363 were up‐regulated in men. In both cohorts, the strongest up‐regulated biomarkers in women were leptin and fatty acid binding protein‐4, compared to matrix metalloproteinase‐3 in men. Similar findings were replicated in a subset of patients from both cohorts matched by age and LVEF. Pathway over‐representation analysis revealed increased activity of pathways associated with lipid metabolism in women, and neuro‐inflammatory response in men (all p < 0.0001). Conclusion: In two independent cohorts of HF patients, biomarkers associated with lipid metabolic pathways were observed in women, while biomarkers associated with neuro‐inflammatory response were more active in men. Differences in inflammatory and metabolic pathways may contribute to sex differences in clinical phenotype observed in HF, and provide useful insights towards development of tailored HF therapies.


  • Open Access

    Pathophysiological pathways in patients with heart failure and atrial fibrillation

    by Bernadet T Santema, Vicente Artola Arita, Iziah E Sama, Mariëlle Kloosterman, Maarten P van Den Berg, Hans L A Nienhuis, Isabelle C Van Gelder, Peter van der Meer, Faiez Zannad, Marco Metra, et al.

    Atrial fibrillation (AF) and heart failure (HF) are two growing epidemics that frequently co-exist. We aimed to gain insights into the underlying pathophysiological pathways in HF patients with AF by comparing circulating biomarkers using pathway overrepresentation analyses. From a panel of 92 biomarkers from different pathophysiological domains available in 1620 patients with HF, we first tested which biomarkers were dysregulated in patients with HF and AF (n = 648) compared with patients in sinus rhythm (n = 972). Secondly, pathway overrepresentation analyses were performed to identify biological pathways linked to higher plasma concentrations of biomarkers in patients who had HF and AF. Findings were validated in an independent HF cohort (n = 1219, 38% with AF). Patient with AF and HF were older, less often women, and less often had a history of coronary artery disease compared with those in sinus rhythm. In the index cohort, 24 biomarkers were up-regulated in patients with AF and HF. In the validation cohort, eight biomarkers were up-regulated, which all overlapped with the 24 biomarkers found in the index cohort. The strongest up-regulated biomarkers in patients with AF were spondin-1 (fold change 1.18, P = 1.33 × 10−12), insulin-like growth factor-binding protein-1 (fold change 1.32, P = 1.08 × 10−8), and insulin-like growth factor-binding protein-7 (fold change 1.33, P = 1.35 × 10−18). Pathway overrepresentation analyses revealed that the presence of AF was associated with activation amyloid-beta metabolic processes, amyloid-beta formation, and amyloid precursor protein catabolic processes with a remarkable consistency observed in the validation cohort. In two independent cohorts of patients with HF, the presence of AF was associated with activation of three pathways related to amyloid-beta. These hypothesis-generating results warrant confirmation in future studies.


  • Open Access

    Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF

    by Matteo Pagnesi, Marianna Adamo, Iziah E. Sama, Stefan D. Anker, John G. Cleland, Kenneth Dickstein, Gerasimos S. Filippatos, Chim C. Lang, Leong L. Ng, Piotr Ponikowski, et al.

    Aims: Few data regarding the prevalence and prognostic impact of mitral regurgitation (MR) in patients with worsening chronic or new‐onset acute heart failure (HF) are available. We investigated the role of MR in the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT‐CHF). Methods and results: We performed a retrospective post‐hoc analysis including patients from both the index and validation BIOSTAT‐CHF cohorts with data regarding MR status. The primary endpoint was a composite of all‐cause death or HF hospitalization. Among 4023 patients included, 1653 patients (41.1%) had moderate–severe MR. Compared to others, patients with moderate–severe MR were more likely to have atrial fibrillation and chronic kidney disease and had larger left ventricular (LV) dimensions, lower LV ejection fraction (LVEF), worse quality of life, and higher plasma concentrations of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP). A primary outcome event occurred in 697 patients with, compared to 836 patients without, moderate–severe MR [Kaplan–Meier 2‐year estimate: 42.2% vs. 35.3%; hazard ratio (HR) 1.28; 95% confidence interval (CI) 1.16–1.41; log‐rank P < 0.0001]. The association between MR and the primary endpoint remained significant after adjusting for baseline variables and the previously validated BIOSTAT‐CHF risk score (adjusted HR 1.11; 95% CI 1.00–1.23; P = 0.041). Subgroup analyses showed a numerically larger impact of MR on the primary endpoint in patients with lower LVEF, larger LV end‐diastolic diameter, and higher plasma NT‐proBNP. Conclusions: Moderate–severe MR is common in patients with worsening chronic or new‐onset acute HF and is strongly associated with outcome, independently of other features related to HF severity.


  • Open Access

    Differences in biomarkers and molecular pathways according to age for patients with HFrEF

    by João Pedro Ferreira, Wouter Ouwerkerk, Bernadet T Santema, Dirk J van Veldhuisen, Chim C Lang, Leong L Ng, Stefan D Anker, Kenneth Dickstein, Marco Metra, John G F Cleland, et al.

    Aims : Elderly patients with heart failure with reduced ejection fraction (HFrEF) have worse prognosis and less often receive guideline-recommended therapies. We aim to better understand the underlying pathophysiological processes associated with ageing in HFrEF potentially leading to targeted therapies in this vulnerable population. Methods and results : From a panel of 363 cardiovascular biomarkers available in 1611 patients with HFrEF in the BIOSTAT-CHF index cohort and cross-validated in 823 patients in the BIOSTAT-CHF validation cohort, we tested which biomarkers were dysregulated in patients aged >75 vs. <65 years. Second, pathway overrepresentation analyses were performed to identify biological pathways linked to higher plasma concentrations of biomarkers in elderly vs. younger patients. After adjustment, multiple test correction [false discovery rate (FDR) 1%], and cross-validation, 27/363 biomarkers were associated with older age, 22 positively and 5 negatively. The biomarkers that were positively associated with older age were associated with tumour cell regulation, extra-cellular matrix organization, and inflammatory processes, whereas biomarkers negatively associated with older age were associated with pathways that may point to cell proliferation and tumourigenesis. Among the 27 biomarkers, WFDC2 (WAP four-disulphide core domain protein 2)—that broadly functions as a protease inhibitor—was associated with older age and had the strongest association with all outcomes. No protein-by-sex interaction was observed. Conclusions : In elderly HFrEF patients, pathways associated with extra-cellular matrix organization, inflammatory processes, and tumour cell regulation were activated, while pathways associated with tumour proliferation functions were down-regulated. These findings may help in a better understanding of the ageing processes in HFrEF and identify potential therapeutic targets.


  • Open Access

    Circulating plasma angiotensin-converting enzyme 2 concentration is elevated in patients with kidney disease and diabetes

    by Iziah E Sama, Adriaan A Voors

    This commentary refers to ‘Circulating plasma angiotensin-converting enzyme 2 concentrations in patients with kidney disease’, by I.M. Schmidt et al., doi: 10.1093/eurheartj/ehaa523.


  • Top Cited Papers
    Open Access

    Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors

    by Iziah E Sama, Alice Ravera, Bernadet T Santema, Harry van Goor, Jozine M ter Maaten, John G F Cleland, Michiel Rienstra, Alex W Friedrich, Nilesh J Samani, Leong L Ng, et al.

    The current pandemic coronavirus SARS-CoV-2 infects a wide age group but predominantly elderly individuals, especially men and those with cardiovascular disease. Recent reports suggest an association with use of renin–angiotensin–aldosterone system (RAAS) inhibitors. Angiotensin-converting enzyme 2 (ACE2) is a functional receptor for coronaviruses. Higher ACE2 concentrations might lead to increased vulnerability to SARS-CoV-2 in patients on RAAS inhibitors. We measured ACE2 concentrations in 1485 men and 537 women with heart failure (index cohort). Results were validated in 1123 men and 575 women (validation cohort). The median age was 69 years for men and 75 years for women. The strongest predictor of elevated concentrations of ACE2 in both cohorts was male sex (estimate = 0.26, P < 0.001; and 0.19, P < 0.001, respectively). In the index cohort, use of ACE inhibitors, angiotensin receptor blockers (ARBs), or mineralocorticoid receptor antagonists (MRAs) was not an independent predictor of plasma ACE2. In the validation cohort, ACE inhibitor (estimate = –0.17, P = 0.002) and ARB use (estimate = –0.15, P = 0.03) were independent predictors of lower plasma ACE2, while use of an MRA (estimate = 0.11, P = 0.04) was an independent predictor of higher plasma ACE2 concentrations. In two independent cohorts of patients with heart failure, plasma concentrations of ACE2 were higher in men than in women, but use of neither an ACE inhibitor nor an ARB was associated with higher plasma ACE2 concentrations. These data might explain the higher incidence and fatality rate of COVID-19 in men, but do not support previous reports suggesting that ACE inhibitors or ARBs increase the vulnerability for COVID-19 through increased plasma ACE2 concentrations.


  • Open Access

    A Network Analysis to Identify Pathophysiological Pathways Distinguishing Ischaemic from Non-Ischaemic Heart Failure

    by Iziah E. Sama, Rebecca J. Woolley, Jan F. Nauta, Simon P.R. Romaine, Jasper Tromp, Jozine M. ter Maaten, Peter van der Meer, Carolyn S.P. Lam, Nilesh J. Samani, Leong L. Ng, et al.

    Aims: Heart failure (HF) is frequently caused by an ischaemic event (e.g. myocardial infarction) but might also be caused by a primary disease of the myocardium (cardiomyopathy). In order to identify targeted therapies specific for either ischaemic or non-ischaemic HF, it is important to better understand differences in underlying molecular mechanisms. Methods and results: We performed a biological physical protein–protein interaction network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic HF. First, differentially expressed plasma protein biomarkers were identified in 1160 patients enrolled in the BIOSTAT-CHF study, 715 of whom had ischaemic HF and 445 had non-ischaemic HF. Second, we constructed an enriched physical protein–protein interaction network, followed by a pathway over-representation analysis. Finally, we identified key network proteins. Data were validated in an independent HF cohort comprised of 765 ischaemic and 100 non-ischaemic HF patients. We found 21/92 proteins to be up-regulated and 2/92 down-regulated in ischaemic relative to non-ischaemic HF patients. An enriched network of 18 proteins that were specific for ischaemic heart disease yielded six pathways, which are related to inflammation, endothelial dysfunction superoxide production, coagulation, and atherosclerosis. We identified five key network proteins: acid phosphatase 5, epidermal growth factor receptor, insulin-like growth factor binding protein-1, plasminogen activator urokinase receptor, and secreted phosphoprotein 1. Similar results were observed in the independent validation cohort. Conclusions: Pathophysiological pathways distinguishing patients with ischaemic HF from those with non-ischaemic HF were related to inflammation, endothelial dysfunction superoxide production, coagulation, and atherosclerosis. The five key pathway proteins identified are potential treatment targets specifically for patients with ischaemic HF.


  • Relationship Between Left Ventricular Ejection Fraction and Cardiovascular Outcomes Following Hospitalization for Heart Failure: Insights from the RELAX-AHF-2 Trial

    by Satit Janwanishstaporn, Siting Feng, John Teerlink, Marco Metra, Gad Cotter, Beth A. Davison, G. Michael Felker, Gerasimos Filippatos, Peter Pang, Piotr Ponikowski, et al.

    Aims Although left ventricular ejection fraction (LVEF) is routinely used to categorize patients with heart failure (HF), whether it predicts outcomes after hospitalization for acute heart failure (AHF) is uncertain. Consequently, we assessed the relationship between LVEF and cardiovascular (CV) outcomes in a large, well characterized cohort of patients hospitalized for AHF. Methods and results The 6128 patients from the RELAX‐AHF‐2 trial who had LVEF measured during AHF hospitalization were separated into LVEF quartiles and the relationship between LVEF and a composite of CV mortality and rehospitalization for HF or renal failure through 180 days was assessed. We found progressively lower risk for this composite outcome as LVEF increased (hazard ratio 0.95, 95% confidence interval 0.93–0.98 per 5% LVEF increase, P < 0.001) that was driven predominantly by decreased risk for rehospitalization. The smoothed spline curve depicting risk remained stable as LVEF decreased until reaching approximately 40%, at which point risk increased progressively with further reductions in LVEF. Significant differences between LVEF quartiles for post‐discharge CV risk were seen in patients with an ischaemic aetiology or with a history of HF preceding index hospitalization, but were less robust in patients with non‐ischaemic aetiology and absent in those with de novo HF. Conclusion In patients hospitalized with AHF, CV events over 180 days were more frequent in patients with lower LVEF. This was due predominantly to a significant increase in risk for HF/renal failure rehospitalization but not in either CV or all‐cause mortality. LVEF had greater prognostic value in patients with ischaemic aetiology or pre‐existing HF.


  • Distinct Pathological Pathways in Patients With Heart Failure and Diabetes

    by Jasper Tromp, Adriaan A. Voors, Abhinav Sharma, João P. Ferreira, Wouter Ouwerkerk, Hans L. Hillege, Karla A. Gomez, Kenneth Dickstein, Stefan D. Anker, Marco Metra, et al.